US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
NZ250844A
(en)
|
1993-04-07 |
1996-03-26 |
Pfizer |
Treatment of non-insulin dependant diabetes with peptides; composition
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
US5641757A
(en)
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
ATE493998T1
(de)
|
1996-08-08 |
2011-01-15 |
Amylin Pharmaceuticals Inc |
Pharmazeutische zusammensetzung mit einem exendin-4-peptid
|
CA2264243C
(en)
|
1996-08-30 |
2004-10-05 |
Novo Nordisk A/S |
Glp-1 derivatives
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
ATE304864T1
(de)
|
1997-01-07 |
2005-10-15 |
Amylin Pharmaceuticals Inc |
Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US6723530B1
(en)
|
1997-02-05 |
2004-04-20 |
Amylin Pharmaceuticals, Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
JP2001513512A
(ja)
|
1997-08-08 |
2001-09-04 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
新規なエキセンディン作動剤化合物
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
DE69838916T2
(de)
|
1997-11-14 |
2008-12-18 |
Amylin Pharmaceuticals, Inc., San Diego |
Neuartige exendin agonisten
|
DE69839021T3
(de)
|
1997-11-14 |
2013-08-08 |
Amylin Pharmaceuticals, Llc |
Neuartige exendin agonisten
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
DE69840106D1
(de)
|
1998-01-09 |
2008-11-20 |
Amylin Pharmaceuticals Inc |
Formulierungen für amylin peptidagonisten mit insulin
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
WO1999046283A1
(en)
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
AU2612599A
(en)
|
1998-03-13 |
1999-10-11 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
CN1209166C
(zh)
|
1998-06-12 |
2005-07-06 |
埃米林药品公司 |
含有与胰高血糖素样肽1的受体结合的化合物的组合物的制药用途
|
AU776514B2
(en)
|
1998-08-10 |
2004-09-09 |
General Hospital Corporation, The |
Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
|
BR9913857A
(pt)
|
1998-09-17 |
2001-06-12 |
Lilly Co Eli |
Formulações de proteìna
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
CA2358107C
(en)
|
1998-12-22 |
2011-08-23 |
Eli Lilly And Company |
Shelf-stable formulation of glucagon-like peptide-1
|
EP1143989B1
(en)
|
1999-01-14 |
2006-12-13 |
Amylin Pharmaceuticals, Inc. |
Exendins for glucagon suppression
|
PT1140145E
(pt)
|
1999-01-14 |
2005-11-30 |
Amylin Pharmaceuticals Inc |
Formulacoes novas de agonistas de exendina e metodos para a sua administracao
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
DE60040333D1
(de)
|
1999-03-17 |
2008-11-06 |
Novo Nordisk As |
Verfahren zur acylierung von peptiden und proteinen
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
CN1372570A
(zh)
|
1999-04-30 |
2002-10-02 |
安米林药品公司 |
修饰的exendin和exendin激动剂
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
EA003922B1
(ru)
|
1999-05-17 |
2003-10-30 |
Конджачем, Инк. |
Продолжительно действующие инсулинотропные пептиды
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US6482799B1
(en)
|
1999-05-25 |
2002-11-19 |
The Regents Of The University Of California |
Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
US6972319B1
(en)
|
1999-09-28 |
2005-12-06 |
Bayer Pharmaceuticals Corporation |
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
CA2396157A1
(en)
|
2000-01-10 |
2001-07-19 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
|
CA2402733A1
(en)
|
2000-03-14 |
2001-09-20 |
Burkhard Goke |
Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
|
WO2001087322A2
(en)
|
2000-05-17 |
2001-11-22 |
Bionebraska, Inc. |
Peptide pharmaceutical formulations
|
CN1462191B
(zh)
|
2000-05-19 |
2013-07-24 |
埃米林药品公司 |
Glp-1用于制备治疗急性冠脉综合征的药物的用途
|
WO2002016309A1
(en)
|
2000-08-18 |
2002-02-28 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US7507714B2
(en)
|
2000-09-27 |
2009-03-24 |
Bayer Corporation |
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
|
WO2002034285A2
(en)
|
2000-10-20 |
2002-05-02 |
Coolidge Thomas R |
Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
|
PL209550B1
(pl)
|
2000-12-07 |
2011-09-30 |
Lilly Co Eli |
Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulinoniezależną i kompozycja do leczenia pacjentów z otyłością
|
EP2186824A3
(en)
|
2000-12-13 |
2010-09-22 |
Eli Lilly & Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
GB2371227A
(en)
|
2001-01-10 |
2002-07-24 |
Grandis Biotech Gmbh |
Crystallisation - resistant aqueous growth hormone formulations
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
US7144863B2
(en)
|
2001-06-01 |
2006-12-05 |
Eli Lilly And Company |
GLP-1 formulations with protracted time action
|
ATE382057T1
(de)
|
2001-06-28 |
2008-01-15 |
Novo Nordisk As |
Stabile formulierung von modifiziertem glp-1
|
EP2053406A3
(en)
|
2001-07-16 |
2009-06-24 |
caprotec bioanalytics GmbH |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
WO2003020201A2
(en)
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
EP1448222A4
(en)
|
2001-10-19 |
2006-05-17 |
Lilly Co Eli |
BIPHASIC MIXTURES OF GLP-1 AND INSULIN
|
ES2425738T3
(es)
|
2001-12-21 |
2013-10-17 |
Human Genome Sciences, Inc. |
Proteínas de fusión de la albúmina
|
EP1463752A4
(en)
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
CN1332711C
(zh)
|
2002-02-20 |
2007-08-22 |
埃米球科技有限公司 |
施用glp-1分子的方法
|
EP1478394B1
(en)
|
2002-02-27 |
2008-07-30 |
Immunex Corporation |
Stabilized TNFR-Fc composition comprising arginine
|
US20040209255A1
(en)
|
2002-03-11 |
2004-10-21 |
Hk Pharmaceuticals, Inc. |
Compounds and methods for analyzing the proteome
|
US7141240B2
(en)
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
WO2003084563A1
(en)
|
2002-04-04 |
2003-10-16 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
US6861236B2
(en)
|
2002-05-24 |
2005-03-01 |
Applied Nanosystems B.V. |
Export and modification of (poly)peptides in the lantibiotic way
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
AU2003232172A1
(en)
|
2002-06-14 |
2003-12-31 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
ES2327328T3
(es)
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
Glp-1 y procedimientos para el tratamiento de la diabetes.
|
US20070065469A1
(en)
|
2002-07-09 |
2007-03-22 |
Michael Betz |
Liquid formulations with high concentration of human growth hormone (high) comprising glycine
|
WO2004004780A1
(en)
|
2002-07-09 |
2004-01-15 |
Sandoz Ag |
Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
|
US20040038865A1
(en)
|
2002-08-01 |
2004-02-26 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
CA2493478C
(en)
|
2002-08-01 |
2014-11-18 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
US20080260838A1
(en)
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
PL216134B1
(pl)
|
2002-08-21 |
2014-03-31 |
Boehringer Ingelheim Pharma |
8-[3-aminopiperydyn-1-ylo]-ksantyny, kompozycja farmaceutyczna je zawierająca, zastosowanie związków oraz sposób ich wytwarzania
|
AU2003268621B2
(en)
|
2002-10-02 |
2009-01-15 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
DE60335743D1
(de)
|
2002-11-20 |
2011-02-24 |
Neuronova Ab |
Verbindungen und verfahren zur erhöhung der neurogenese
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
WO2004056313A2
(en)
|
2002-12-17 |
2004-07-08 |
Amylin Pharmaceuticals, Inc. |
Prevention and treatment of cardiac arrhythmias
|
US20040209803A1
(en)
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
PT1620118E
(pt)
|
2003-04-08 |
2014-10-16 |
Yeda Res & Dev |
Fármacos peguilados de modo reversível
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
AU2004240630B2
(en)
|
2003-05-15 |
2010-10-07 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
DK2644206T3
(da)
|
2003-05-23 |
2019-06-11 |
Nektar Therapeutics |
PEG-derivater indeholdende to PEG-kæder
|
EP1631308B1
(en)
|
2003-05-30 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
EP2292254A3
(en)
|
2003-06-03 |
2011-12-14 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
ATE529126T1
(de)
|
2003-06-03 |
2011-11-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische peptid zusammensetzungen
|
PL1633391T3
(pl)
|
2003-06-03 |
2012-03-30 |
Novo Nordisk As |
Stabilizowane farmaceutycznie kompozycje peptydowe
|
PL1633390T3
(pl)
|
2003-06-03 |
2012-06-29 |
Novo Nordisk As |
Stabilizowane kompozycje farmaceutyczne peptydu glp-1
|
US8921311B2
(en)
|
2003-08-01 |
2014-12-30 |
Mannkind Corporation |
Method for treating hyperglycemia
|
KR101159559B1
(ko)
|
2003-08-05 |
2012-06-26 |
노보 노르디스크 에이/에스 |
신규의 인슐린 유도체
|
KR20060106812A
(ko)
|
2003-08-21 |
2006-10-12 |
노보 노르디스크 에이/에스 |
라세미화 아미노산을 포함하는 폴리펩티드의 분리
|
US20060247167A1
(en)
|
2003-09-01 |
2006-11-02 |
Novo Nordisk A/S |
Stable formulations of peptides
|
WO2005021022A2
(en)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Stable formulations of peptides
|
WO2005028516A2
(en)
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
JP4800959B2
(ja)
|
2003-11-13 |
2011-10-26 |
ノヴォ ノルディスク アー/エス |
糖尿病及び過食症を治療するためのglp−1ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
US20050281879A1
(en)
|
2003-11-14 |
2005-12-22 |
Guohua Chen |
Excipients in drug delivery vehicles
|
US20050106214A1
(en)
|
2003-11-14 |
2005-05-19 |
Guohua Chen |
Excipients in drug delivery vehicles
|
EP1750752A2
(en)
|
2003-11-20 |
2007-02-14 |
Neuronova AB |
Compounds and methods for increasing neurogenesis
|
SI1687019T1
(en)
|
2003-11-20 |
2018-04-30 |
Novo Nordisk A/S |
PROPILED GLIKO-CONTAINING PEPTIDAL FORMULATIONS OPTIMAL FOR MANUFACTURING AND FOR USE IN INJECTION DEVICES
|
ATE517119T1
(de)
|
2003-12-03 |
2011-08-15 |
Novo Nordisk As |
Einzelketteninsulin
|
CA2549011A1
(en)
|
2003-12-10 |
2005-06-30 |
Nektar Therapeutics Al, Corporation |
Compositions comprising two different populations of polymer-active agent conjugates
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
US8603969B2
(en)
|
2004-02-11 |
2013-12-10 |
Amylin Pharmaceuticals, Llc |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
EP2233497A3
(en)
|
2004-02-11 |
2011-01-12 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides and methods for making and using them
|
EP2417980A1
(en)
|
2004-02-11 |
2012-02-15 |
Amylin Pharmaceuticals Inc. |
Hybrid polypeptides with selectable properties
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
US20060110423A1
(en)
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
WO2005110425A1
(en)
|
2004-04-15 |
2005-11-24 |
Alkermes, Inc. |
Polymer-based sustained release device
|
US20090069226A1
(en)
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
WO2005117584A2
(en)
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
EP1758575A1
(en)
|
2004-06-11 |
2007-03-07 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
EP1773878B1
(en)
|
2004-07-19 |
2015-03-04 |
Biocon Limited |
Insulin-oligomer conjugates, formulations and uses thereof
|
WO2006091231A2
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
EA200700391A1
(ru)
|
2004-08-03 |
2007-10-26 |
Байорексис Текнолоджи, Инк. |
Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
|
JP4965446B2
(ja)
|
2004-08-31 |
2012-07-04 |
ノヴォ ノルディスク アー/エス |
ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス(ヒドロキシメチル)アミノメタンの使用
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
JP2008513384A
(ja)
|
2004-09-17 |
2008-05-01 |
ノボ ノルディスク アクティーゼルスカブ |
インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物
|
EP3173072A1
(en)
|
2004-10-01 |
2017-05-31 |
Ramscor, Inc. |
Conveniently implantable sustained release drug compositions
|
EP2330126B1
(en)
|
2004-10-07 |
2015-12-23 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
US7595294B2
(en)
|
2004-10-08 |
2009-09-29 |
Transition Therapeutics, Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
US20090036355A1
(en)
|
2004-10-13 |
2009-02-05 |
Sanjay Bhanot |
Antisense Modulation of PTP1B Expression
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
BRPI0517341A
(pt)
|
2004-11-12 |
2008-10-07 |
Novo Nordisk As |
composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1
|
JP5248113B2
(ja)
|
2004-11-12 |
2013-07-31 |
ノヴォ ノルディスク アー/エス |
ペプチドの安定な処方
|
CN112618700A
(zh)
|
2004-11-12 |
2021-04-09 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
EP2769990A3
(en)
|
2004-12-02 |
2015-02-25 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
|
BRPI0518559A2
(pt)
|
2004-12-13 |
2008-11-25 |
Amylin Pharmaceuticals Inc |
motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos
|
JP5243041B2
(ja)
|
2004-12-21 |
2013-07-24 |
ネクター セラピューティックス |
安定化ポリマーチオール試薬
|
EP1831252B1
(en)
|
2004-12-22 |
2009-07-01 |
Eli Lilly And Company |
Glp-1 analog fusion protein formulations
|
CA2599594A1
(en)
|
2004-12-24 |
2006-07-13 |
Amylin Pharmaceuticals, Inc. |
Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
CN100540565C
(zh)
|
2005-01-14 |
2009-09-16 |
无锡宏创医药科技有限公司 |
修饰的Exendins及其应用
|
WO2006082588A2
(en)
|
2005-02-07 |
2006-08-10 |
Pharmalight Inc. |
Method and device for ophthalmic administration of active pharmaceutical ingredients
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
MX2007009760A
(es)
|
2005-02-11 |
2007-11-07 |
Amylin Pharmaceuticals Inc |
Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables.
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
DK1888103T3
(da)
|
2005-04-11 |
2012-04-23 |
Amylin Pharmaceuticals Inc |
Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
|
WO2006114396A1
(en)
|
2005-04-24 |
2006-11-02 |
Novo Nordisk A/S |
Injection device
|
WO2006125763A1
(en)
|
2005-05-25 |
2006-11-30 |
Novo Nordisk A/S |
Stabilized polypeptide formulations
|
CN101217940B
(zh)
|
2005-06-06 |
2013-03-27 |
卡穆鲁斯公司 |
Glp-1类似物制剂
|
GB0511986D0
(en)
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
ATE553124T1
(de)
|
2005-06-13 |
2012-04-15 |
Imp Innovations Ltd |
Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
|
BRPI0611872B8
(pt)
|
2005-06-16 |
2021-05-25 |
Nektar Therapeutics |
reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
|
CN101257926A
(zh)
|
2005-08-04 |
2008-09-03 |
尼克塔治疗亚拉巴马公司 |
G-csf部分与聚合物的轭合物
|
WO2007016764A1
(en)
|
2005-08-06 |
2007-02-15 |
Qinghua Wang |
Composition and method for prevention and treatment of type i diabetes
|
CA2617649A1
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
DK1971362T3
(en)
|
2005-08-19 |
2015-01-26 |
Amylin Pharmaceuticals Llc |
Exendin for treating diabetes and reducing body weight
|
DK1928423T3
(en)
|
2005-09-14 |
2016-02-29 |
Mannkind Corp |
A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
|
BRPI0616195A2
(pt)
|
2005-09-20 |
2011-06-14 |
Novartis Ag |
uso de um inibidor de dpp-iv para reduzir eventos hipoglicÊmicos
|
US8759290B2
(en)
|
2005-10-18 |
2014-06-24 |
Biocon Limited |
Oral glucagon-like peptide conjugates for metabolic diseases
|
US20070099820A1
(en)
|
2005-10-19 |
2007-05-03 |
Smartcells, Inc. |
Polymer-drug conjugates
|
CN101534846B
(zh)
|
2005-11-07 |
2014-11-05 |
印第安纳大学研究及科技有限公司 |
显示生理学溶解性和稳定性的胰高血糖素类似物
|
WO2007053946A1
(en)
|
2005-11-09 |
2007-05-18 |
Conjuchem Biotechnologies Inc. |
Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
|
MX2008007075A
(es)
|
2005-12-02 |
2008-11-12 |
Mdrna Inc |
Formulacion farmaceutica para incrementar la permeabilidad epitelial por peptido regulador de glucosa.
|
WO2007064691A1
(en)
|
2005-12-02 |
2007-06-07 |
Nabil Habib Lab |
Treatment of cancer and other diseases
|
WO2007067964A2
(en)
|
2005-12-08 |
2007-06-14 |
Nastech Pharmaceutical Company Inc. |
Mucosal delivery of stabilized formulations of exendin
|
ES2390286T3
(es)
|
2005-12-16 |
2012-11-08 |
Nektar Therapeutics |
Conjugados poliméricos de GLP-1
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8178495B2
(en)
|
2008-06-27 |
2012-05-15 |
Duke University |
Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
|
JP2009525946A
(ja)
|
2005-12-20 |
2009-07-16 |
デューク・ユニヴァーシティ |
増強された薬理学的性質を有する活性物質を送達するための方法および組成物
|
CA2637569C
(en)
|
2006-01-18 |
2013-01-08 |
Yuhua Li |
Pharmaceutical compositions with enhanced stability
|
AU2007212147A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
US7704953B2
(en)
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
US20090186817A1
(en)
|
2006-03-21 |
2009-07-23 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
EP2015769A4
(en)
|
2006-04-13 |
2013-12-25 |
Ipsen Pharma |
PHARMACEUTICAL COMPOSITIONS OF HGLP-1, EXENDINE 4 AND THEIR ANALOGUES
|
AU2007238000B2
(en)
|
2006-04-14 |
2013-01-17 |
Mannkind Corporation |
Glucagon-like peptide 1(GLP-1) pharmaceutical formulations
|
DE202006006388U1
(de)
|
2006-04-20 |
2007-08-30 |
Tegometall (International) Ag |
Regal-Fachboden
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EP2029160A2
(en)
|
2006-05-12 |
2009-03-04 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
WO2007139589A1
(en)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
US20100029554A1
(en)
|
2006-05-26 |
2010-02-04 |
Amylin Pharmaceuticals, Inc. |
Composition and Methods for Treatment of Congestive Heart Failure
|
EP2038423B1
(en)
|
2006-06-21 |
2012-12-26 |
Biocon Limited |
A method of producing biologically active polypeptide having insulinotropic activity
|
DK2494959T3
(en)
|
2006-07-05 |
2015-02-23 |
Foamix Pharmaceuticals Ltd |
Foam Bart dicarboxylsyrebærestof and pharmaceutical compositions thereof
|
AU2007278994B2
(en)
|
2006-07-24 |
2013-08-15 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
US7928186B2
(en)
|
2006-08-02 |
2011-04-19 |
Phoenix Pharmaceuticals, Inc. |
Cell permeable bioactive peptide conjugates
|
EP2046284A1
(en)
|
2006-08-04 |
2009-04-15 |
Nastech Pharmaceutical Company Inc. |
Compositions for intranasal delivery of human insulin and uses thereof
|
EP3421031A1
(en)
|
2006-08-09 |
2019-01-02 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
CA2660835A1
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable propperties
|
WO2008023050A1
(en)
|
2006-08-25 |
2008-02-28 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
CN102827284B
(zh)
|
2006-11-14 |
2015-07-29 |
上海仁会生物制药股份有限公司 |
带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
|
EP2124883A2
(en)
|
2006-12-12 |
2009-12-02 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical formulations and methods for making the same
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
US20090098130A1
(en)
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
CN101663317A
(zh)
*
|
2007-01-05 |
2010-03-03 |
CovX科技爱尔兰有限公司 |
胰高血糖素样蛋白-1受体glp-1r激动剂化合物
|
RU2432361C2
(ru)
*
|
2007-01-05 |
2011-10-27 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
|
EP2124974B1
(en)
|
2007-01-05 |
2017-03-15 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
WO2008098212A2
(en)
|
2007-02-08 |
2008-08-14 |
Diobex, Inc. |
Extended release formulations of glucagon and other peptides and proteins
|
AU2008216265B2
(en)
|
2007-02-15 |
2014-04-03 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
US8420598B2
(en)
|
2007-04-20 |
2013-04-16 |
B & L Delipharm Corp. |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
CN101715340A
(zh)
|
2007-04-23 |
2010-05-26 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
WO2008134425A1
(en)
|
2007-04-27 |
2008-11-06 |
Cedars-Sinai Medical Center |
Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
|
US7829664B2
(en)
|
2007-06-01 |
2010-11-09 |
Boehringer Ingelheim International Gmbh |
Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
|
AU2008258548B2
(en)
|
2007-06-08 |
2014-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Long-acting transient polymer conjugates of exendin
|
JP5385266B2
(ja)
|
2007-06-15 |
2014-01-08 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
US20100196405A1
(en)
|
2007-07-10 |
2010-08-05 |
Kingman Ng |
GLP-1 Fc FUSION PROTEIN FORMULATION
|
EP3260129A1
(en)
|
2007-08-03 |
2017-12-27 |
Eli Lilly and Company |
An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
SG185940A1
(en)
|
2007-08-30 |
2012-12-28 |
Curedm Group Holdings Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
JP5606314B2
(ja)
|
2007-09-05 |
2014-10-15 |
ノボ・ノルデイスク・エー/エス |
A−b−c−d−で誘導体化されたペプチドとその治療用途
|
EP2650006A1
(en)
|
2007-09-07 |
2013-10-16 |
Ipsen Pharma S.A.S. |
Analogues of exendin-4 and exendin-3
|
WO2009055742A2
(en)
|
2007-10-24 |
2009-04-30 |
Mannkind Corporation |
Delivery of active agents
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
AU2008316634B2
(en)
|
2007-10-24 |
2014-02-27 |
Mannkind Corporation |
Method of preventing adverse effects by GLP-1
|
CA2707861A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
ES2558155T3
(es)
|
2007-10-30 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
|
CN101861333A
(zh)
|
2007-11-16 |
2010-10-13 |
诺沃-诺迪斯克有限公司 |
包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
|
WO2009067268A1
(en)
|
2007-11-23 |
2009-05-28 |
Michael Rothkopf |
Methods of enhancing diabetes resolution
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
WO2009075859A2
(en)
|
2007-12-11 |
2009-06-18 |
Conjuchem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
JP2011511778A
(ja)
|
2008-01-30 |
2011-04-14 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
エステルに基づいたペプチドプロドラッグ
|
LT2237799T
(lt)
|
2008-02-01 |
2019-07-25 |
Ascendis Pharma A/S |
Provaistas, apimantis besiskaidantį linkerį
|
MY161108A
(en)
|
2008-02-06 |
2017-04-14 |
Biocon Ltd |
Fermentation medias and processes thereof
|
WO2009114959A1
(zh)
|
2008-03-20 |
2009-09-24 |
中国人民解放军军事医学科学院毒物药物研究所 |
可注射用缓释药物制剂及其制备方法
|
CA2720864C
(en)
|
2008-04-07 |
2017-07-04 |
National Institute Of Immunology |
Compositions useful for the treatment of diabetes and other chronic disorder
|
AU2009244799B2
(en)
|
2008-05-07 |
2014-11-20 |
Merrion Research Iii Limited |
Compositions of GnRH related compounds and processes of preparation
|
EP2303313B1
(en)
|
2008-05-21 |
2015-10-28 |
Amylin Pharmaceuticals, LLC |
Exendins to lower cholestrol and triglycerides
|
EP2288918A1
(en)
|
2008-05-23 |
2011-03-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist bioassays
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
AU2009257311B2
(en)
|
2008-06-13 |
2014-12-04 |
Mannkind Corporation |
A dry powder inhaler and system for drug delivery
|
EA020326B9
(ru)
|
2008-06-17 |
2015-03-31 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
|
CL2009001424A1
(es)
|
2008-06-17 |
2010-04-30 |
Univ Indiana Res & Tech Corp |
Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
|
TWI541023B
(zh)
|
2008-06-17 |
2016-07-11 |
印第安納大學科技研究公司 |
在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
|
JP5604297B2
(ja)
|
2008-06-17 |
2014-10-08 |
株式会社糖鎖工学研究所 |
糖鎖付加glp−1ペプチド
|
JP2011528709A
(ja)
|
2008-07-21 |
2011-11-24 |
トランスファーマ メディカル リミテッド |
インクレチンおよびインクレチン模倣ペプチドの持続性送達用経皮システム
|
WO2010013012A2
(en)
|
2008-08-01 |
2010-02-04 |
Lund University Bioscience Ab |
Novel polypeptides and uses thereof
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
BR122013025625B1
(pt)
|
2008-10-17 |
2021-08-03 |
Sanofi-Aventis Deutschland Gmbh |
Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
|
EP2373681B1
(en)
|
2008-12-10 |
2017-01-18 |
Glaxosmithkline LLC |
Pharmaceutical compositions of albiglutide
|
DK2370461T3
(da)
|
2008-12-15 |
2013-12-16 |
Zealand Pharma As |
Glucagonanaloger
|
EA020520B1
(ru)
|
2008-12-15 |
2014-11-28 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
DK2370462T3
(da)
|
2008-12-15 |
2014-09-08 |
Zealand Pharma As |
Glucagon-analoger
|
CN102282167B
(zh)
|
2008-12-15 |
2014-08-13 |
西兰制药公司 |
胰高血糖素类似物
|
CA2747499A1
(en)
|
2008-12-19 |
2010-06-24 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
CN101538323B
(zh)
|
2009-01-13 |
2012-05-09 |
深圳翰宇药业股份有限公司 |
一种纯化艾塞那肽的方法
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
TWI528982B
(zh)
|
2009-03-04 |
2016-04-11 |
曼凱公司 |
改良的乾粉藥物輸送系統
|
JP5608686B2
(ja)
|
2009-03-05 |
2014-10-15 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
後退可能な針を備えた薬物送達デバイス
|
US8642544B2
(en)
|
2009-04-01 |
2014-02-04 |
Amylin Pharmaceuticals, Llc |
N-terminus conformationally constrained GLP-1 receptor agonist compounds
|
US8992886B2
(en)
|
2009-04-06 |
2015-03-31 |
Board Of Regents, The University Of Texas System |
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
|
KR101183262B1
(ko)
|
2009-04-22 |
2012-09-14 |
(주)알테오젠 |
체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
CN101559041B
(zh)
|
2009-05-19 |
2014-01-15 |
中国科学院过程工程研究所 |
粒径均一的多肽药物缓释微球或微囊制剂及制备方法
|
EP3189868A1
(en)
|
2009-05-20 |
2017-07-12 |
Sanofi-Aventis Deutschland GmbH |
Bung for drug containing cartridges in drug delivery devices comprising an electronic coding feature
|
JP5698223B2
(ja)
|
2009-05-20 |
2015-04-08 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
薬物送達デバイスにおける薬物含有カートリッジ用の栓
|
EP2435061A4
(en)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
|
US20120172298A1
(en)
|
2009-06-11 |
2012-07-05 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
MX2011013625A
(es)
|
2009-06-16 |
2012-01-20 |
Univ Indiana Res & Tech Corp |
Compuestos glucagon activo de receptor de gip.
|
EP2448965A4
(en)
|
2009-07-02 |
2015-02-11 |
Angiochem Inc |
MULTIMEPEPTID CONJUGATES AND ITS USES
|
SG177609A1
(en)
|
2009-07-13 |
2012-02-28 |
Zealand Pharma As |
Acylated glucagon analogues
|
CN101601646B
(zh)
|
2009-07-22 |
2011-03-23 |
南京凯瑞尔纳米生物技术有限公司 |
治疗糖尿病的鼻腔滴剂及其制备方法
|
WO2011011675A1
(en)
|
2009-07-23 |
2011-01-27 |
Zelos Therapeutics, Inc. |
Pharmaceutically acceptable formulations/compositions for peptidyl drugs
|
JP5738291B2
(ja)
|
2009-07-31 |
2015-06-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリンリンカー複合体を含むプロドラッグ
|
WO2011017835A1
(en)
|
2009-08-11 |
2011-02-17 |
Nanjing University |
Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
EA201290123A1
(ru)
|
2009-09-30 |
2012-10-30 |
Глаксо Груп Лимитед |
Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
|
US20110097386A1
(en)
|
2009-10-22 |
2011-04-28 |
Biodel, Inc. |
Stabilized glucagon solutions
|
US9610329B2
(en)
|
2009-10-22 |
2017-04-04 |
Albireo Pharma, Inc. |
Stabilized glucagon solutions
|
WO2011049713A2
(en)
|
2009-10-22 |
2011-04-28 |
Biodel Inc. |
Stabilized glucagon solutions
|
AU2010312655A1
(en)
|
2009-10-30 |
2012-05-03 |
Glytech, Inc. |
Glycosylated form of antigenic GLP-1 analogue
|
EP2496249B1
(en)
|
2009-11-03 |
2016-03-09 |
Amylin Pharmaceuticals, LLC |
Glp-1 receptor agonist for use in treating obstructive sleep apnea
|
MY159565A
(en)
|
2009-11-13 |
2017-01-13 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
DK2498802T3
(en)
|
2009-11-13 |
2015-04-13 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
|
KR20120092714A
(ko)
|
2009-12-15 |
2012-08-21 |
메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 |
비만 및 다른 대사성 질환의 치료를 위한 ppar 절약형 티아졸리딘디온 및 복합제
|
PL2512470T3
(pl)
|
2009-12-15 |
2017-06-30 |
Octeta Therapeutics, Llc |
Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych
|
AU2010340058A1
(en)
|
2009-12-15 |
2012-06-21 |
Metabolic Solutions Development Company, Llc |
PPAR-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
|
CA2783468C
(en)
|
2009-12-15 |
2018-10-09 |
Metabolic Solutions Development Company, Llc |
Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
|
DK2513140T3
(en)
|
2009-12-16 |
2016-01-18 |
Novo Nordisk As |
Double-acylated GLP-1 derivatives
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
CN102933200B
(zh)
|
2009-12-18 |
2015-11-25 |
莱迪杜德制药公司 |
包含磷脂的单相凝胶组合物
|
CN101798588B
(zh)
|
2009-12-21 |
2015-09-09 |
上海仁会生物制药股份有限公司 |
Glp-1受体激动剂生物学活性测定方法
|
AR079345A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
EP2525809B1
(en)
|
2010-01-20 |
2016-08-03 |
Zealand Pharma A/S |
Glucagon-glp1 dual agonists for use in the treatment of cardiac conditions
|
RU2012136450A
(ru)
|
2010-01-27 |
2014-03-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
|
NZ601496A
(en)
|
2010-02-01 |
2013-12-20 |
Sanofi Aventis Deutschland |
Cartridge holder, drug delivery device and method for securing a cartridge in a cartridge holder
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
AU2011231503C1
(en)
|
2010-03-26 |
2016-03-03 |
Novo Nordisk A/S |
Novel glucagon analogues
|
JP6050746B2
(ja)
|
2010-05-13 |
2016-12-21 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Gタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
|
US9127088B2
(en)
|
2010-05-13 |
2015-09-08 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
AU2011254559B2
(en)
|
2010-05-20 |
2014-09-04 |
Glaxo Group Limited |
Improved anti-serum albumin binding variants
|
US8263554B2
(en)
|
2010-06-09 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
Methods of using GLP-1 receptor agonists to treat pancreatitis
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
US8636711B2
(en)
|
2010-06-14 |
2014-01-28 |
Legacy Emanuel Hospital & Health Center |
Stabilized glucagon solutions and uses therefor
|
RU2571331C1
(ru)
|
2010-06-21 |
2015-12-20 |
Маннкайнд Корпорейшн |
Системы и способы доставки сухих порошковых лекарств
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
WO2011162830A2
(en)
|
2010-06-24 |
2011-12-29 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
RU2580317C2
(ru)
|
2010-06-24 |
2016-04-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
|
WO2011163473A1
(en)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
WO2012012352A2
(en)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
US20120046225A1
(en)
|
2010-07-19 |
2012-02-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Stable glucagon formulations for the treatment of hypoglycemia
|
AU2011282745A1
(en)
|
2010-07-28 |
2013-03-14 |
Amylin Pharmaceuticals, Llc |
GLP-1 receptor agonist compounds having stabilized regions
|
CN102397558B
(zh)
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
EP3028720A1
(en)
|
2010-09-28 |
2016-06-08 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action
|
ES2533601T3
(es)
|
2010-11-03 |
2015-04-13 |
Arecor Limited |
Nueva composición que comprende glucagón
|
ES2732818T3
(es)
|
2010-11-09 |
2019-11-26 |
Mannkind Corp |
Composición que comprende un agonista de receptores de serotonina y una dicetopiperazina para tratar migrañas
|
EP2460552A1
(en)
|
2010-12-06 |
2012-06-06 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with locking arrangement for dose button
|
US9278123B2
(en)
|
2010-12-16 |
2016-03-08 |
Novo Nordisk A/S |
Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
EP2654767A4
(en)
|
2010-12-22 |
2014-05-21 |
Amylin Pharmaceuticals Inc |
GLP-1 RECEPTOR AGONISTS FOR ISLAND CELL TRANSPLANTATION
|
BR112013015861A2
(pt)
*
|
2010-12-22 |
2018-06-05 |
Marcadia Biotech Inc |
métodos para reduzir ganho de peso ou induzir perda de peso, e para tratar hiperglicemia, reduzir níveis de glicose no sangue, ou normalizar níveis de glicose no sangue.
|
SG191194A1
(en)
*
|
2010-12-22 |
2013-07-31 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting gip receptor activity
|
CN102532301B
(zh)
|
2010-12-31 |
2014-09-03 |
上海医药工业研究院 |
一类新型的Exendin-4类似物及其制备方法
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CN102100906A
(zh)
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
DK2683364T3
(en)
|
2011-03-10 |
2017-02-27 |
Xeris Pharmaceuticals Inc |
Stable formulations for parenteral injection of peptide drugs.
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
CN102718868A
(zh)
|
2011-03-30 |
2012-10-10 |
上海华谊生物技术有限公司 |
定点单取代聚乙二醇化Exendin类似物及其制备方法
|
EP2694095B1
(en)
|
2011-04-05 |
2018-03-07 |
Longevity Biotech, Inc. |
Compositions comprising glucagon analogs and methods of making and using the same
|
EP2696897A2
(en)
|
2011-04-11 |
2014-02-19 |
Yeda Research and Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
CN102766204B
(zh)
|
2011-05-05 |
2014-10-15 |
天津药物研究院 |
胰高血糖素样肽-1突变体多肽及其制备方法和其应用
|
DK2710031T3
(en)
|
2011-05-18 |
2018-01-02 |
Mederis Diabetes Llc |
IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
|
EP2714069A4
(en)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
LONG-TERM CONJUGATES WITH TWO HORMONES
|
UA113626C2
(xx)
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
UA126465C2
(uk)
|
2011-06-10 |
2022-10-12 |
Ханмі Сайенс Ко., Лтд. |
Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
|
KR102002783B1
(ko)
|
2011-06-10 |
2019-07-24 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
|
EP3502129B1
(en)
|
2011-06-17 |
2021-04-07 |
Hanmi Science Co., Ltd. |
A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
|
MX340172B
(es)
|
2011-06-17 |
2016-06-28 |
Halozyme Inc |
Formulaciones estables de una enzima degradadora de hialuronano.
|
JP6179864B2
(ja)
|
2011-06-22 |
2017-08-16 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
グルカゴン/glp−1レセプタコ−アゴニスト
|
CN103748109A
(zh)
|
2011-06-22 |
2014-04-23 |
印第安纳大学研究及科技有限公司 |
胰高血糖素/glp-1受体共同激动剂
|
US20140220134A1
(en)
|
2011-06-24 |
2014-08-07 |
Astrazeneca Pharamceuticals LP |
Method for treating diabetes with extended release formulation of glp-1 receptor agonists
|
KR101357117B1
(ko)
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
US9944687B2
(en)
|
2011-07-04 |
2018-04-17 |
Imperial Innovations Limited |
Compounds and their effects on feeding behaviour
|
US9382304B2
(en)
|
2011-07-08 |
2016-07-05 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
CA2843586A1
(fr)
|
2011-08-10 |
2013-02-14 |
Adocia |
Solution injectable d'au moins une insuline basale
|
EP2747832A4
(en)
|
2011-08-24 |
2015-01-07 |
Phasebio Pharmaceuticals Inc |
FORMULATIONS OF ACTIVE AGENTS FOR PROLONGED RELEASE
|
CN103189389B
(zh)
|
2011-09-03 |
2017-08-11 |
深圳市健元医药科技有限公司 |
新的glp‑ⅰ类似物及其制备方法和用途
|
AU2012311484B2
(en)
|
2011-09-23 |
2017-04-13 |
Novo Nordisk A/S |
Novel glucagon analogues
|
MX359329B
(es)
|
2011-10-28 |
2018-09-25 |
Sanofi Aventis Deutschland |
Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.
|
CN102363633B
(zh)
|
2011-11-16 |
2013-11-20 |
天津拓飞生物科技有限公司 |
胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
|
BR112014007124A2
(pt)
|
2011-11-17 |
2017-06-13 |
Univ Indiana Res & Tech Corp |
superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
|
CA2852716C
(en)
|
2011-11-29 |
2015-11-17 |
Jurox Pty Ltd |
Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
|
RS63244B1
(sr)
|
2011-12-16 |
2022-06-30 |
Modernatx Inc |
Kompozicije modifikovane mrna
|
BR112014014898A2
(pt)
|
2011-12-22 |
2020-10-27 |
Pfizer Inc. |
processo para purificar uma amostra de anticorpo h38c2, ou variante do mesmo, e composição compreendendo o referido h38c2
|
EP2793931A2
(en)
|
2011-12-23 |
2014-10-29 |
Zealand Pharma A/S |
Glucagon analogues
|
JP2015503565A
(ja)
|
2011-12-29 |
2015-02-02 |
ラティチュード ファーマシューティカルズ インコーポレイテッドLatitude Pharmaceuticals, Inc. |
安定化させたグルカゴンナノエマルジョン
|
BR112014016889A8
(pt)
|
2012-01-09 |
2017-07-04 |
Adocia |
composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
|
US20150133373A1
(en)
|
2012-03-28 |
2015-05-14 |
Amylin Pharmaceuticals, Llc |
Transmucosal delivery of engineered polypeptides
|
WO2013148871A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides
|
CN108949772A
(zh)
|
2012-04-02 |
2018-12-07 |
现代泰克斯公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
EP2833892A4
(en)
|
2012-04-02 |
2016-07-20 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
|
CN102649947A
(zh)
|
2012-04-20 |
2012-08-29 |
无锡和邦生物科技有限公司 |
一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用
|
WO2013163162A1
(en)
|
2012-04-24 |
2013-10-31 |
Amylin Pharmaceuticals, Llc |
Site-specific enzymatic modification of exendins and analogs thereof
|
US20130289241A1
(en)
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
WO2013182217A1
(en)
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
WO2013164484A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
EP2664374A1
(en)
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
CN103421094A
(zh)
|
2012-05-24 |
2013-12-04 |
上海医药工业研究院 |
一种具有epo类似活性的多肽化合物
|
US20150174209A1
(en)
|
2012-05-25 |
2015-06-25 |
Amylin Pharmaceuticals. Llc |
Insulin-pramlintide compositions and methods for making and using them
|
CA2875743A1
(en)
*
|
2012-06-14 |
2013-12-19 |
Sanofi |
Exendin-4 peptide analogues
|
BR112014031671A2
(pt)
*
|
2012-06-21 |
2018-08-07 |
Hoffmann La Roche |
análogos de glucagon exibindo atividade de receptor gip
|
US9802012B2
(en)
|
2012-07-12 |
2017-10-31 |
Mannkind Corporation |
Dry powder drug delivery system and methods
|
AR091866A1
(es)
|
2012-07-23 |
2015-03-04 |
Zealand Pharma As |
Analogos del glucagon
|
AR094821A1
(es)
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
EP2934562A1
(en)
|
2012-08-14 |
2015-10-28 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
EP2931300A1
(en)
|
2012-08-14 |
2015-10-21 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
CN102816244A
(zh)
|
2012-08-23 |
2012-12-12 |
无锡和邦生物科技有限公司 |
一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
|
CN102827270A
(zh)
|
2012-09-13 |
2012-12-19 |
无锡和邦生物科技有限公司 |
一种聚乙二醇化艾塞那肽衍生物及其用途
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
EP2895506A1
(en)
|
2012-09-17 |
2015-07-22 |
Imperial Innovations Limited |
Peptide analogues of glucagon and glp1
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
KR102311517B1
(ko)
|
2012-11-06 |
2021-10-14 |
한미약품 주식회사 |
옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
US11065304B2
(en)
|
2012-11-20 |
2021-07-20 |
Mederis Diabetes, Llc |
Peptide pharmaceuticals for insulin resistance
|
TWI674270B
(zh)
|
2012-12-11 |
2019-10-11 |
英商梅迪繆思有限公司 |
用於治療肥胖之升糖素與glp-1共促效劑
|
LT2934568T
(lt)
|
2012-12-21 |
2018-02-12 |
Sanofi |
Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai
|
CN103908657A
(zh)
|
2012-12-31 |
2014-07-09 |
复旦大学附属华山医院 |
胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
|
EP3238734A1
(en)
|
2013-03-14 |
2017-11-01 |
Medimmune Limited |
Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
|
BR112015023071A2
(pt)
|
2013-03-14 |
2017-07-18 |
Univ Indiana Res & Tech Corp |
conjugados de insulina-incretina
|
CN105324125A
(zh)
|
2013-03-15 |
2016-02-10 |
印第安纳大学研究及科技有限公司 |
具有长效的前体药物
|
MY174727A
(en)
|
2013-04-18 |
2020-05-11 |
Novo Nordisk As |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
JP2014227368A
(ja)
|
2013-05-21 |
2014-12-08 |
国立大学法人帯広畜産大学 |
糖尿病および高血糖状態の処置のためのグルカゴンアナログ
|
CN103304660B
(zh)
|
2013-07-12 |
2016-08-10 |
上海昂博生物技术有限公司 |
一种利拉鲁肽的合成方法
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
TWI666220B
(zh)
|
2013-10-17 |
2019-07-21 |
丹麥商西蘭製藥公司 |
醯化升糖素類似物
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
MX369770B
(es)
|
2013-11-06 |
2019-11-21 |
Zealand Pharma As |
Compuestos agonistas triples de glucagón-glp-1-gip.
|
WO2015086732A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues
|
WO2015086731A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/gip受體促效劑
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽-4(exendin-4)胜肽類似物
|
CN103665148B
(zh)
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
CN103980358B
(zh)
|
2014-01-03 |
2016-08-31 |
杭州阿诺生物医药科技股份有限公司 |
一种制备利拉鲁肽的方法
|
CN105960249B
(zh)
|
2014-01-09 |
2021-03-16 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
|
BR112016013832A2
(pt)
|
2014-01-09 |
2017-08-08 |
Sanofi Sa |
Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
|
TW201625670A
(zh)
*
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
CN106519015B
(zh)
|
2014-09-23 |
2020-04-17 |
深圳市图微安创科技开发有限公司 |
胃泌酸调节素类似物
|